Leaving the study early: lack of efficacy ‐ long term · patients with schizophrenia
RISPERIDONE DEPOT may leads to lower leaving the study early: lack of efficacy ‐ long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
1 finding from 1 review
Adverse events: Any glucose‐related ‐ medium/long term · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Any glucose‐related ‐ medium/long term compared with ATYPICAL DEPOT ANTIPSYCHOTICS (PALIPERIDONE PALMITATE) (low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher leaving the study early for any reason ‐ long term compared with TYPICAL DEPOT ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
Adverse events: related to movement disorder, weight gain, prolactin levels and glucose metabolism ‐ medium/long term ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes global state: Relapse (any reason) ‐ long term Number of… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Mental state ‐ improvement · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ long term compared with GENERAL ORAL ANTIPSYCHOTICS (moderate certainty).
1 finding from 1 review
Intervention not reported
Long‐term change in health status · Smokers who cannot or do not want to quit smoking
1 finding from 1 review
Intervention not reported
Long term adverse effects or toxicity from observational studies
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause mortality: longest · infants 1 to 6 months of age
The intervention showed no clear difference in all‐cause mortality: longest (moderate certainty).
1 finding from 1 review
Mortality within the longest · adults or children with bleeding
Thromboelastography (TEG) or thromboelastometry (ROTEM) may leads to lower mortality longest compared with any comparison (low certainty).
1 finding from 1 review
Intervention not reported
Mortality (all cause) Long‐term · people with chronic ischaemic heart disease and congestive heart failure
The intervention may leads to lower mortality (all cause) Long‐term (low certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal myocardial infarction Long‐term · people with chronic ischaemic heart disease and congestive heart failure
The intervention may leads to lower non‐fatal myocardial infarction Long‐term (low certainty).
1 finding from 1 review
Intervention not reported
Rehospitalisation due to heart failure Long‐term · people with chronic ischaemic heart disease and congestive heart failure
The intervention showed no clear difference in rehospitalisation due to heart failure Long‐term (low certainty).
1 finding from 1 review
Intervention not reported
Arrhythmias Long‐term · people with chronic ischaemic heart disease and congestive heart failure
The intervention may leads to lower arrhythmias Long‐term (low certainty).
1 finding from 1 review
Intervention not reported
Composite MACE Long‐term · people with chronic ischaemic heart disease and congestive heart failure
The intervention showed no clear difference in composite MACE Long‐term (low certainty).
1 finding from 1 review
Intervention not reported
LVEF (%) measured by MRI Long‐term · people with chronic ischaemic heart disease and congestive heart failure
1 finding from 1 review